Xtandi approved in Japan for CRPC
This article was originally published in Scrip
Executive Summary
Astellas has received marketing approval in Japan for Xtandi (enzalutamide) for use in previously treated patients with castration-resistant prostate cancer (CRPC), marking the first such clearance in this market for the oral androgen receptor signalling inhibitor.